September is both World Alzheimer’s Month and Healthy Aging Month. That pairing isn’t a coincidence — it’s a clue we’ve been slow to follow. Nearly two-thirds of Americans living with Alzheimer’s are women, and longevity alone doesn’t explain the gap. A growing body of research points to menopause as a critical, under-addressed inflection point for women’s brain health: the drop in estrogen that defines the transition is linked to changes in memory, cognition, and long-term dementia risk. It’s one of the clearest biological threads connecting a women’s health milestone to a national health crisis. Health tech has largely ignored it.

The problem: Menopause care has been treated as a hot-flash problem, not a brain problem. Millions of women move through a transition with real cognitive symptoms — brain fog, memory lapses, slowed processing — with almost nothing connecting what they’re feeling to their long-term neurological risk, and almost no tools built to track or act on it. A well-documented biological risk window sits wide open, and the technology industry has mostly looked past it.

Why now: The science has moved faster than the market. In just the past few years, research linking menopause to brain aging and Alzheimer’s risk has gone from a niche question to a recognized inflection point in women’s health. Investment in menopause tech is finally catching up to the size of the population it serves — but funding doesn’t equal proof. As more menopause apps and platforms launch, women need a way to tell which ones are grounded in evidence and which are just well-designed products riding a trend. That distinction is the whole ballgame, and right now almost nobody is making it for them.

The evidence: This is the gap HITLAB is built to close. Through the HITLAB x Versalie™ Innovation Challenge, HITLAB has worked directly with the next generation of menopause-focused health tech companies — including thePause™, an AI-driven menopause management platform that took first place for its work personalizing support at scale. The stakes are structural: roughly 6,000 women enter menopause every day in the U.S., against a certified menopause provider-to-patient ratio as high as 1 to 30,000. When specialist access is that scarce, the technology stepping into the gap has to be trustworthy by design — not by assumption.

“Alzheimer’s awareness can’t stop at symptoms and diagnosis — it has to reach back into the life stages that shape risk, and menopause is one of the biggest ones we’ve been ignoring,” said Divya Verma. “Women are living through a well-documented window for brain health with almost no infrastructure built around it. That’s exactly where evidence-validated technology should be stepping in — not another wellness app making promises it can’t back up.”

If Alzheimer’s disproportionately affects women, closing that gap starts earlier than most people think — at menopause, not at diagnosis. This September, that’s the case worth making alongside the awareness.